Myriad Genetics (MYGN) Gross Profit (2009 - 2026)

Myriad Genetics (MYGN) has reported Gross Profit for 18 consecutive years, with $137.6 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Gross Profit rose 2.53% year-over-year to $137.6 million; the TTM figure through Mar 2026 stood at $580.0 million (changed 0.34% YoY), while the FY2025 annual figure was $576.6 million, down 1.5% from the prior year.
• Gross Profit slipped to $137.6 million in Q1 2026 per MYGN's latest filing, from $146.8 million in the prior quarter.
• Across five years, Gross Profit topped out at $151.8 million in Q2 2025 and bottomed at $106.0 million in Q3 2022.
• Historically, Gross Profit has averaged $134.9 million across 5 years, with a median of $135.0 million in 2023.
• Annual changes were most pronounced in 2022 — Gross Profit decreased 29.45% — and 2023, when it increased 26.7%.
• Myriad Genetics' Gross Profit stood at $123.9 million in 2022, then grew by 8.96% to $135.0 million in 2023, then climbed by 11.78% to $150.9 million in 2024, then slipped by 2.72% to $146.8 million in 2025, then retreated by 6.27% to $137.6 million in 2026.
• Business Quant data shows MYGN's Gross Profit at $137.6 million in Q1 2026, $146.8 million in Q4 2025, and $143.8 million in Q3 2025.